Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
← catalyst calendarNCT07140900 · readout in 586 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
60estimated
Sites
16
Countries
Australia, Switzerland, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-07 | actual | When the study began enrolling |
| Primary completion | 2028-03-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
- Drug: Xaluritamig — also filed as AMG 509
- Drug: Darolutamide
- Drug: Abiraterone
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment-emergent Adverse Events
measured Up to approximately 2.5 years
Number of Participants with Treatment-related Adverse Events
measured Up to approximately 2.5 years
Number of Participants with Clinically Significant Changes in Vital Signs
measured Up to approximately 2.5 years
Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests
measured Up to approximately 2.5 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed